The HR6A and HR6B genes, homologs of the yeast RAD6 gene, encode ubiquitin conjugating enzymes that are required for postreplication repair (PRR) of DNA and damage-induced mutagenesis. We show here that consistent with its role as a PRR protein, HR6 protein (referred as RAD6) expression is cell cycle regulated, with maximal levels expressed in late S/G2 phases of the cell cycle. Exposure of MCF10A cells to adriamycin (ADR) causes enhancement in the levels of RAD6B mRNA and protein.
Introduction
Many endogenous and exogenous agents are capable of damaging DNA. DNA lesions are subject to removal by DNA repair pathways. Many of the otherwise lethal replication-blocking lesions are typically repaired by nucleotide excision repair and base excision repair pathways. However, these mechanisms cannot often repair lesions in the genome due to limited repair capacity or poorly recognized damage. During DNA replication, unrepaired lesions can impose road blocks for the replication machinery. If these pathways are saturated or unable to repair such lesions prior to the onset of S phase, cell death could ensue. To prevent cell death in such circumstances, all cells contain DNA damage tolerance pathways. DNA damage tolerance acts to reinitiate replication in the presence of damage, without lesion removal. This better 'safe than sorry philosophy' has apparently been adapted by all organisms, and this genetic network is highly conserved throughout evolution (Broomfield et al., 2001) .
In the yeast Saccharomyces cerevisiae, lesion bypass is composed of error-free and error-prone repair processes that are jointly regulated by RAD6 and designed to promote the completion of DNA synthesis (Lawrence, 1994) . Not only does the RAD6 pathway account for a substantial fraction of budding yeast's resistance to DNA-damaging agents, but is also responsible for the generation of mutations induced by such damage (Lawrence, 1982) . The RAD6 gene encodes a 17 kDa protein (Reynolds et al., 1985) , which is one of a group of ubiquitin conjugating (E2, UBC) enzymes (Jentsch et al., 1987) that covalently adds ubiquitin to certain lysine residues. The yeast RAD6/UBC2/E2 is involved in a variety of processes including DNA repair, mutagenesis and cell proliferation (Haynes and Kunz, 1981) . The RAD6 pathway regulates post-translational modification of target proteins with ubiquitin, which commits them to rapid proteolysis. rad6 mutants possess an extremely pleiotropic phenotype that includes slow growth, severe defects in induced mutagenesis, extreme sensitivity to UV, X-ray and chemical mutagens, and hypersensitivity to antifolate drug metabolites . All the functions performed by RAD6 protein appear to result from ubiquitination since replacement of the conserved Cys 88 with serine produces a totally null phenotype (Sung et al., , 1991 .
That DNA recovery processes analogous to yeast exist in humans is reinforced by the discovery of human homologs of the RAD6 gene (Koken et al., 1991) . Unlike in yeast and Drosophila, the RAD6 human homolog is encoded by two genes, HHR6A (RAD6A) and HHR6B (RAD6B), that complement the DNA repair and UV mutagenesis defects of the yeast rad6 mutant (Koken et al., 1991) . RAD6A and RAD6B share B96% identical amino-acid residues and are localized on human chromosome Xq24-q25 and 5q23-q31, respectively (Koken et al., 1992) . The human and yeast RAD6 homologs share B70% sequence identity. Both human RAD6 genes have overlapping constitutive functions related to chromatin conformation that involve ubiquitin-mediated histone degradation . In whole-animal studies, loss of the mouse RAD6B gene results in male infertility due to impaired spermatogenesis , which is postulated to result from defects in histone ubiquitination and chromatin modification . HR6B or RAD6B is overexpressed in mouse and human breast cancer lines and tumors, and constitutive overexpression of RAD6B induces formation of multinucleated cells, centrosome amplification, abnormal mitosis, aneuploidy and transformation (Shekhar et al., 2002) . Following exposure of human breast epithelial cells to DNA-damaging drugs, RAD6 is found to exist in supramolecular complexes with p53 and p14ARF, and the stability of the complexes appears to correlate with p53 stability (Lyakhovich and Shekhar, 2003) . Thus, RAD6 appears to be an important ubiquitin conjugating enzyme that may play a significant role in the maintenance of genomic integrity of mammalian cells. Imbalances in the levels and activity of RAD6 lead to chromosomal instability and transformation in vitro (Shekhar et al., 2002) . To further elucidate the functional role of RAD6 in normal human breast cells, we have evaluated the regulation of its expression during cell cycle and DNA damage-induced responses, its recruitment to the chromatin following DNA damage, and the consequences of RAD6 overexpression or depletion on postreplication repair (PRR) capacity and sensitivity to commonly used chemotherapeutic drugs. Our results show that, consistent with its role as a PRR protein, maximal levels of RAD6 are expressed during late S/G2 phase of cell cycle, and that adriamycin (ADR)-stimulated increases in RAD6B mRNA expression occur at the transcriptional level. The ability of MCF10A human breast epithelial cells to tolerate DNA damage induced by ADR and cisplatin correlates with RAD6 expression levels in that cells stably transfected with antisense RAD6B expression vector are PRRcompromised and hypersensitive to the drugs. These findings suggest an important role for RAD6 in normal human breast cells and imply that RAD6 overexpression frequently found in human breast cancers could potentially impact the fidelity of PRR pathways and hence the chemosensitivity of cancer cells.
Results

Regulation of RAD6 expression during cell cycle
In order to determine the steady-state levels of RAD6 protein expression during cell cycle, MCF10A cells were synchronized by growing in serum-deficient media and released from G0 phase by stimulating them with complete medium for 8-10 h, followed by overnight treatment with 5 mM 5-hydroxyurea, a G1/S-blocking drug, in complete medium. Cells were washed to remove 5-hydroxyurea and further incubated in drug-free complete medium. Cells were harvested at various times for the analysis of cell cycle progression and RAD6 protein expression by flow cytometry and Western blot analysis, respectively. As shown in Figure 1a and b, RAD6 expression is low during the quiescent phase when 495% of cells are in G0/G1 phases. Stimulation of cells with complete medium resulted in a slight increase in RAD6 levels. However, a negligible increase in RAD6 levels is observed in cells arrested in Figure 1 RAD6 protein is maximally expressed in late S/G2 phase of cell cycle. MCF10A cells were made quiescent by serum starvation (Q) and quiescent cells released by stimulation with complete medium for 8 h (Q.8 h). Cells were then treated with 5-hydroxyurea overnight (HU), rinsed and incubated in drug-free media for 4 (HU, 4 h), 8 (HU, 8 h), 16 (HU, 16 h) or 24 h (HU, 24 h) for analysis of RAD6 protein levels by Western blot analysis (a) and cell cycle phase distribution by flow cytometry (b) RAD6 influences drug sensitivity A Lyakhovich and MPV Shekhar G1/S phase by hydroxyurea treatment. Release from G1/S block by removing hydroxyurea and allowing cells to progress through cell cycle caused gradual but discernible increases in RAD6 protein levels that reached maximal levels only during late S/G2 phases of cell cycle, and decreased as the cells entered a new G1 phase (Figure 1a and b) . These data are consistent with those reported in S. cerevisiae, as yeast lacking RAD6 display defects in transit through the S/G2 phase of the cell cycle (Ellison et al., 1991) and suggest that RAD6 protein expression profiles in human breast cells are consistent with its role as a PRR protein.
Regulation of RAD6B mRNA expression by ADR Semiquantitative RT-PCR was performed to assess the effects of ADR, a potent anthracycline topoisomerase II inhibitor and one of the most widely used chemotherapeutic drugs, on RAD6B mRNA expression in normal MCF10A cells. Cells were treated with 0.1 mg/ml ADR for 1 h, rinsed and allowed to undergo recovery for various periods of time in drug-free media. After normalizing for GAPDH expression, a two-fold increase in RAD6B cDNA products relative to untreated controls was observed at 2-8 h following ADR treatment, and the levels further increased to approximately four-fold by 48 h post-ADR treatment (Figure 2a) .
Since the peptide used to generate RAD6 antibody is conserved 100% in mouse and human RAD6B, and 91% in human RAD6A protein, the results of Western blot analysis cannot distinguish RAD6A and B forms. Hence data from Western analysis are indicated as RAD6 protein rather than RAD6B. Although a detectable increase in RAD6 protein levels was detected by 2 h of post-treatment, a steady increase in RAD6 protein levels was detected from 8 h post-treatment.
After normalization with b-actin, the levels of RAD6 protein were B3-and 6-fold higher at 8 and 48 h posttreatment, respectively, as compared to untreated samples ( Figure 2b ). This increase in RAD6 levels is not due to cell cycle effect, as 490% of MCF10A cells treated with ADR are arrested in G2/M phase at least until 72 h post-treatment.
To determine whether the induction of RAD6B mRNA levels observed in ADR-treated MCF10A cells reflected enhanced transcription and/or increased stability of RAD6B transcripts, actinomycin D was added to prevent any new gene transcription. MCF10A cells were treated with ADR for 1 h followed by replacement with drug-free medium. Cells were allowed to recover for 4 h at which time both control and ADR-treated cells were incubated with actinomycin D, and RAD6B mRNA levels were monitored over the following 8 h period by the slot blot method using a RAD6B-specific cDNA probe. As shown in Figure 3a , despite steady-state levels of RAD6B mRNA being higher at every time point in ADR-treated samples when compared to the corresponding untreated samples, addition of the RNA pol II inhibitor actinomycin D abolished both basal and ADR-induced RAD6 transcription at similar rates (Figures 3b and c) . These data suggest that the higher levels of RAD6B transcripts attained by exposure to ADR arose primarily from enhanced transcription and not from the effects on RAD6B mRNA stability. As the t 1/2 of RAD6B mRNA is B70 min in both control and ADR-treated cells, these data suggest that continual transcription of the RAD6B gene may be required for maintenance of adequate levels of RAD6B and that once transcribed the mRNA is rapidly translated.
Post-transcriptional regulation of RAD6B by ADR
In order to determine if ADR influences translation and/ or stability of the translated RAD6 protein, control and ADR-treated MCF10A cells were prepared as described above, and treated with actinomycin D or cycloheximide to inhibit de novo gene expression or protein synthesis, respectively. The levels of RAD6 protein were analysed by Western blot analysis in cells harvested at 0, 2, 12 or 24 h following actinomycin D or cycloheximide treatment. As shown in Figure 4a and b, RAD6 protein levels were slightly enhanced in control cells exposed to actinomycin D as compared to the corresponding untreated samples. In contrast, addition of actinomycin D to ADR-treated cells caused an B60% decrease in RAD6 protein levels when compared to the corresponding ADR-treated samples, whereas the levels of b-actin were unaffected. It is not clear at present if the differences in actinomycin D effects observed in control and ADR-treated cells reflect real differences in the regulation of RAD6 protein synthesis during normal cell cycle versus that following DNA damage. Inclusion of cycloheximide dramatically reduced RAD6 protein levels in both control and ADR-treated cells. These data suggest that ADR enhances RAD6B expression levels primarily at the transcriptional levels, as inclusion of actinomycin D caused similar decreases in the steadystate levels of ADR-induced RAD6 protein as those caused by cycloheximide. Blots were stripped and reprobed with p53 antibody to ascertain effectiveness of actinomycin D and cycloheximide treatments as the effects of these agents on p53 are well documented, as well as to compare the effects of actinomycin D and cycloheximide on p53 with those on RAD6. Analysis of p53 steady-state levels showed an B3-fold increase in ADR-treated samples as compared to untreated control samples (Figure 4c Addition of cycloheximide caused a dramatic reduction in p53 steady-state levels in control samples and a modest decrease in ADR-treated samples (Figure 4c and d). However, constant but appreciable levels of p53 were maintained in ADR plus cycloheximide-treated samples (Figure 4c and d). This lack of p53 regulation in ADR plus cycloheximide-treated samples probably reflects the absence of de novo synthesized regulatory proteins such as MDM2 and p14ARF. These data are in agreement with previous reports and suggest that ADR-stimulated increase in p53 protein levels reflects regulation at the post-translational level rather than at the transcriptional level (Kim et al., 2001 ).
Constitutive RAD6B overexpression induces resistance to DNA-damaging agents
Since error-free lesion bypass has been suggested to account for most of RAD6-dependent resistance to DNA-damaging agents, we examined the relative sensitivities to cisplatin (a chemotherapeutic drug that induces DNA damage by formation of intra-and interstrand crosslinks) and ADR of MCF10A cells stably transfected with RAD6B (clones 2 and 5), antisense RAD6B (AS2) or empty vector. Following normalization with b-actin, MCF10A-RAD6B clone 2 Figure 4 Effect of actinomycin D and cycloheximide on ADRinduced RAD6 and p53 protein expression. MCF10A cells were either untreated (control) or treated with ADR for 1 h and allowed to recover in drug-free media for 0-24 h. Untreated or ADRtreated cells at 0 h of recovery were also treated with actinomycin D (5 mg/ml) or cycloheximide (10 mg/ml), and RAD6 and b-actin (a) protein levels were determined by Western blot analysis at indicated time points. Blots were stripped and reprobed with p53 CM-1 polyclonal antibody (c). Levels of RAD6B (b) or p53 (d) protein relative to b-actin levels were determined by scanning densitometry and results expressed relative to those at 0 h in the respective groups RAD6 influences drug sensitivity A Lyakhovich and MPV Shekhar and MCF10A-AS2 cells express similar or B10-fold lower levels, respectively, of RAD6 as compared to empty vector-transfected parental cells, and MCF10A-RAD6B clone 5 cells express B20-fold higher levels of RAD6 as compared to vector-transfected parental cells ( Figure 5a ). As shown in Figure 5b , MCF10A-RAD6B-overexpressing clone 5 cells displayed highest resistance to ADR in that doses equivalent to B0.75 mg/ml were required to cause 50% inhibition of cell viability as compared to B0.1 mg/ml for MCF10A-RAD6B clone 2 or vector-transfected MCF10A cells, or 0.05 mg/ml for MCF10A-AS2 cells (Figure 5b) . At low doses of ADR, there was no statistically significant difference in sensitivities to ADR between MCF10A-RAD6B clone 5 and clone 2 or vector control cells, and the presence of ADR-resistant subpopulation(s) was revealed at higher doses of ADR (Figure 5b ). However, a statistically significant (Po0.01) difference in sensitivity at low doses of ADR was evident between AS2 and clone 5 cells. The differences in sensitivities between MCF10A-RAD6B clone 5 and clone 2 or vector control cells are more striking in the presence of cisplatin (Figure 5c ). At every dose of cisplatin, a significant difference (Po0.005) in killing is observed between clone 5 (IC 50 41 mg/ml) and clone 2 or vector control cells (IC 50 o0.1 mg/ml). Similarly, a significant difference in cisplatin-induced cytotoxicity is observed between AS2 (IC 50 o0.05 mg/ml) and clone 2 cells (Po0.01), and between AS2 and clone 5 cells (Po0.001). Analysis of other clones showing similar levels of ectopic RAD6B expression as clone 5 cells (e.g., clone 1; Figure 5a ) exhibited similar magnitudes of drug resistance as clone 5 cells (data not shown). Similarly, other MCF10A clones derived from antisense RAD6B transfection experiments displayed increased sensitivities to cisplatin and ADR (data not shown). These data reveal a correlation between RAD6B expression levels and relative sensitivities to cisplatin and ADR.
In order to determine if the differences in drug sensitivities resulted from alterations in cell proliferation rates, we monitored the growth rates of MCF10A-Neo, MCF10A-RAD6B clone 5, MCF10A-RAD6B clone 2 and MCF10A-AS2 cells. Striking differences in plating efficiencies between AS2 and vector control cells were observed as approximately o50% of AS2 cells efficiently plate down. However, after making corrections for plating efficiencies, no significant difference in proliferation rates were observed between AS2, RAD6B clones and vector control cells as all three cell lines exhibited a doubling time that ranged from 20 to 23 h (Figure 5d ). Although the reasons for the inability of AS2 cells to plate down efficiently are not known, it is possible that cells lacking RAD6 fail to plate down and proliferate, while cells expressing low albeit trace amounts of RAD6 retain their ability to plate down and proliferate.
Treatment with DNA-damaging drug induces recruitment and/or redistribution of RAD6 on the chromatin Presence of RAD6 on the chromatin was determined by formaldehyde fixation, which allows formation of in vivo crosslinks between proteins or between protein and DNA (Solomon and Varshavsky, 1985) . Control and ADR-treated MCF10A cells were fixed with formaldehyde, and the sheared crosslinked chromatin was subjected to isopycnic centrifugation on CsCl. As shown in Figure 6 , phosphohistone H3, a marker that is positively associated with chromatin, was found to be exclusively associated with DNA in nuclear preparations of both control and ADR-treated MCF10A cells. Similarly, the majority of p53 and PCNA were found to be associated with DNA (fractions with higher density) in control MCF10A cells. In contrast, only a small proportion of RAD6 was found to be associated with chromatin in control MCF10A cells, as the majority of RAD6 was present in the upper fractions, that is, fractions with lower density. These data suggest that although RAD6 is present in the nucleus, only a small amount of it is physically associated with DNA in untreated MCF10A cells. However, following ADR treatment, a significant increase in RAD6 that is positively associated with chromatin was observed, and RAD6, PCNA, RAD18 and p53 were all found to colocalize with DNA as well as with phosphohistone H3 (Figure 6 ). Treatment with ADR resulted in enhancement in the levels of p53 associated with the chromatin. This is consistent with ADR-induced post-translational stabilization of p53 (Shieh et al., 1997) as evidenced by the presence of a p53-immunoreactive doublet band ( Figure 6 ). No carboxypeptidase-immunoreactive bands were observed in the fractions, indicating the absence of contaminating cytoplasmic proteins in the nuclear fractions (data not shown). Exposure of MCF10A cells to cisplatin induced similar redistribution of RAD6 to the chromatin (data not shown). These findings suggest that although RAD6 protein is present in the nucleus, its recruitment to the chromatin appears to be modulated by DNA damage.
Postreplication DNA Repair (PRR)
DNA damage-induced lesions are manifested as singlestrand DNA breaks that can be seen by separation of genomic DNA in an alkaline sucrose gradient (Lehman, 1972; Lehman et al., 1975) . After a short incubation, the fragmented genomic DNA is converted into large molecular weight species, similar to DNA of untreated controls. This restoration process is defined as PRR. In order to determine the role of RAD6B in normal human breast epithelial cells, we measured PRR capacity in MCF10A-Neo, MCF10A-RAD6B clone 5 and MCF10A-AS2 cells by the sedimentation velocity method. Figure 7 shows the results of a pulse and pulse-chase experiment with cells that were untreated or treated with cisplatin. Labeling times were adjusted so that approximately equal amounts of DNA were labeled in untreated and cisplatin-treated cells. As shown in Figure 7 , striking differences in sedimentation profiles were observed between control MCF10A-Neo, MCF10A-RAD6B clone 5 and MCF10A-AS2 cells; however, the sedimentation profiles of pulse-labeled control MCF10A-Neo, MCF10A-RAD6B clone 5 and MCF10A-AS2 cells (Figure 7a ) are superimposable on their corresponding pulse-chased profiles (Figure 7a 0 ). The majority of DNA in control vector-transfected MCF10A-Neo and MCF10A-RAD6B clone 5 cells sedimented between 48 and 20 kb, whereas DNA from control MCF10A-AS2 cells peaked close to the 20 kb marker. Examination of the size of newly synthesized DNA in cisplatin-treated cells after a 45 min pulse with 3 H-thymidine showed similar sedimentation profiles in vector-transfected and RAD6B-transfected MCF10A cells, peaking near 20 kb, whereas DNA from MCF10A-AS2 cells was found near the top of the gradient near 5 kb. After a 90 min chase, DNAs from vector-transfected and RAD6B-transfected MCF10A cells were found to migrate between 48 and 20 kb markers, whereas DNA from MCF10A-AS2 cells was observed as a broad band between 20 and 5 kb markers with a significant proportion of DNA close to the 5 kb marker (Figure 7b ). Profiles similar to those in Figure 7 are highly reproducible and were obtained from three separate experiments. These data show that following exposure to cisplatin, MCF10A-AS2 cells, compared to controls, have decreased ability to convert the newly synthesized DNA to higher molecular weight species, a property indicative of poor DNA damage tolerance or impaired PRR capacity. These data are consistent with the data from Figure 5b that show hypersensitivity of MCF10A-AS2 cells to cisplatininduced cytotoxicity.
Figure 6 ADR treatment enhances distribution and localization of RAD6 protein to the chromatin. MCF10A cells, untreated (control) or treated with ADR (0.1 mg/ml, 1 h and allowed to recover for 6 h), were treated with formaldehyde at 371C for 30 min to allow for in vivo crosslinking of proteins or protein-DNA complexes as described in Materials and methods. Nuclei were isolated, lysed, sonicated and subjected to isopycnic centrifugation on CsCl cushions. Fractions were collected from the bottom and analysed for DNA by agarose gel electrophoresis or for the presence of RAD6, p53, RAD18, PCNA, phosphohistone H3 (a chromatin marker) and carboxypeptidase (a cytoplasmic marker) proteins by Western blot analysis. Since no carboxypeptidaseimmunoreactive bands were observed in the fractions, the negative strips are not shown. Note the increase in the localization of RAD6 protein in DNA-containing high-density fractions in ADR-treated cells. Also, note the presence of p53-immunoreactive doublet bands as well as the presence of RAD6, p53, RAD18, PCNA and the positive chromatin marker phosphohisone H3 in DNA-containing fractions in ADR-treated cells
Discussion
Of the three major DNA damage repair pathways, the RAD6 pathway is the most complicated and least characterized (Friedberg et al., 1995) . However, unlike RAD3 nucleotide excision repair pathway yeast mutants, which are extremely sensitive to UV but less to MMS and ionizing radiation, and RAD52 recombination repair pathway mutants, which are extremely sensitive to MMS and ionizing radiation but less sensitive to UV, RAD6 pathway mutants are sensitive to a broad range of DNA-damaging agents, suggesting a shared feature that inhibits DNA synthesis. Genetic analysis in yeast has indicated the importance of lesion bypass in response to DNA damage. The present study characterizes the regulation and consequence of overexpression or lack of HHR6B, the human homolog of the yeast RAD6 protein, on cell proliferation, sensitivity to commonly used chemotherapeutic drugs and PRR capacity of normal human breast cells.
In contrast to the report by Koken et al. (1996) that both mRNA and protein levels of RAD6A and B remain unchanged throughout the cell cycle in HeLa cells, our data show a cell cycle periodicity in RAD6 protein levels in normal MCF10A human breast epithelial cells, with maximal expression in late S/G2 phase. These results are consistent with RAD6 function as a PRR protein and coincide with the cell cycle period at which yeast defective for rad6 are arrested (Kupiec and Simchen, 1984; Ellison et al., 1991) . Treatment of MCF10A cells with ADR causes G2/M arrest (Lyakhovich and Shekhar, 2003) and increases in RAD6B mRNA and protein levels. Our present data show that ADR-mediated increase in RAD6B gene expression occurs primarily via mechanisms involving transcriptional regulation rather than post-transcriptional control of RAD6B mRNA and protein stability. RAD6B mRNA in MCF10A cells has a short half-life, approximately 70 min, which is not altered by ADR treatment. These data suggest that ADR-induced increase in RAD6B mRNA and protein levels is dependent upon sustained transcription and efficient translation.
Our data from in vivo crosslinking experiments further demonstrate that the preferential nuclear localization of RAD6 protein observed in ADR-treated MCF10A cells (Lyakhovich and Shekhar, 2003) is indeed associated with an increase and/or redistribution of RAD6, RAD18, p53 and PCNA proteins to the DNA. Although these data do not confirm, they do suggest H-thymidine for 45 min or chased with 10-fold excess of cold thymidine for 90 min following pulse labeling. Cells were lysed, irradiated briefly and then subjected to ultracentrifugation on alkaline sucrose gradients. Fractions were collected from the bottom, and aliquots of fractions were subjected to TCA precipitation for determination of acid-precipitable radioactivity. Results are expressed as a percent of total TCA-precipitable radioactivity in the samples prior to ultracentrifugation. (a, b) Sedimentation profiles of control and cisplatin-treated cells, respectively. (a 0 , b 0 ) Sedimentation profiles of control and cisplatin-treated cells that were chased with unlabeled thymidine following pulse-labeling. The closed arrowhead, open arrowhead and arrow indicate positions of l DNA, HindIII-cut l DNA and linearized pGL-3 basic vector, respectively RAD6 influences drug sensitivity A Lyakhovich and MPV Shekhar that damage may enable or promote assembly of these proteins, perhaps as complexes, at the sites of DNA damage. RAD6 has been demonstrated to function in the error-free repair pathway, and utilizes RAD6, RAD18, RAD5, Mms2 and Ubc13 (Ulrich and Jentsch, 2000) . All these proteins have been shown to interact at least transiently (Broomfield et al., 1998; Ulrich and Jentsch, 2000; Torres-Ramos et al., 2002) . RAD6-RAD18 dimers (Bailly et al., 1997; Xin et al., 2000) in the presence of REV3 or RAD30 have been implicated in error-prone lesion bypass (Roche et al., 1995; McDonald et al., 1997; Cejka et al., 2001) . Similarly, RAD6 has been found to be a common component in complexes with PCNA (Hoege et al., 2002 ), Bre1 (Wood et al., 2002 and p53 (Lyakhovich and Shekhar, 2003) ; these data suggest that mechanisms regulating expression and activity of RAD6 may be crucial in determining the levels and type of complexes formed by RAD6 with key proteins that are critical for regulation and fidelity of cell cycle checkpoints and preservation of genomic integrity. In this context, we have previously demonstrated that the stability of RAD6-p53 complexes formed appears to correlate with the length of damageinduced G2/M arrest, as metastatic MDA-MB-231 human breast cancer cells display short-lived RAD6-p53 complexes and transient G2/M arrest whereas normal MCF10A cells display stable RAD6-p53 complexes and prolonged G2/M arrest (Lyakhovich and Shekhar, 2003) .
rad6 null mutants of yeast exhibit extreme sensitivity to various DNA-damaging agents, enhanced spontaneous and impaired mutagenesis, lower growth rate and decreased viability under stress conditions (Lawrence, 1994) . MCF10A cells with compromised RAD6B function display a phenotype reminiscent of the corresponding yeast mutant in terms of drug sensitivity. Although no human diseases have been linked to mutations in the PRR pathway genes, these results suggest that RAD6B may play an essential role in DNA damage tolerance and recovery. Since the RAD6 human homolog is encoded by two genes RAD6A and B that share 490% amino-acid sequence identity and functional redundancy, the severe drug sensitivities and impaired PRR capacities observed in MCF10A cells stably transfected with the antisense RAD6B construct may be attributed to the complete loss of lesion bypass as a result of neutralization of both RAD6A and B activities. Our results from growth assays have also shown that MCF10A-AS2 cells have severely impaired ability to plate down as approximately o50% of the cells are able to do so. However, interestingly, after making corrections for plating efficiencies, no significant difference in proliferation rates were observed between AS2 and vector control cells. Although the reasons for the inability of AS2 cells to plate down efficiently are not known, a probable explanation could be that cells retaining the ability to plate down and proliferate are perhaps those expressing trace amounts of RAD6 protein. In the light of our results that RAD6 expression increases during late S/G2 phases of cell cycle, these data would suggest that MCF10A cells depleted of RAD6 are probably most impacted, whereas those expressing minimal but critical levels of RAD6 continue to cycle at similar rates as vector control cells. Alternatively, since a significant proportion of MCF10A-AS2 cells still retain their ability to proliferate at similar rates as parental cells, these data would suggest that whereas RAD6 plays an essential role in growth and proliferation of rapidly dividing organisms such as yeast, it is perhaps not central to MCF10A cell proliferation but assumes an important role upon DNA damage. In this regard, it is interesting to note that MCF10A cells engineered to overexpress RAD6B constitutively exhibit resistance to cisplatin and ADR and are PRR-proficient. Since RAD6 is required for both error-free and error-prone modes of PRR as shown by its epistatic relationship with RAD18, RAD5, RAD30, REV3 and REV7 (Xiao et al., 2000) , it is conceivable that much of the repair activity in RAD6B-overexpressing MCF10A cells is error-prone. This is consistent with their transformed behavior as evidenced by abnormal mitosis, multinucleation, aneuploidy and ability for anchorage-independent growth (Shekhar et al., 2002) .
In summary, we have shown that RAD6 is necessary but not central to normal human breast cell proliferation and growth, and that it plays a vital role following DNA damage via modulation of PRR and sensitivity/ resistance to chemotherapeutic drugs. Since RAD6B overexpression is detected in human breast tumors and constitutive overexpression of exogenous RAD6B induces aneuploidy and transformation, understanding the mechanisms regulating the RAD6B-mediated DNA damage tolerance pathway will shed light on cancer development and response to chemotherapy.
Materials and methods
Cell culture
Culture conditions for cell lines used in this study have been described before (Shekhar et al., 2002) . MCF10A is a human breast epithelial cell line that arose by spontaneous immortalization from cell cultures established from the subcutaneous mastectomy of a woman with fibrocystic disease. MCF10A cells are pseudodiploid, lack tumorigenicity in nude mice and are unable to support anchorage-independent growth (Soule et al., 1990) . Briefly, MCF10A cells were maintained in DMEM/F-12 medium supplemented with 5% horse serum, 0.02 mg/ml EGF, 0.5 mg/ml hydrocortisone, 10 mg/ml insulin, 0.1 mg/ml cholera toxin, 100 U/ml penicillin and 100 mg/ml streptomycin. Cell lines derived from MCF10A stable transfections with wild-type human RAD6B in sense direction (MCF10A-RAD6B clones 2 and 5), antisense direction (MCF10A-a/s RAD6B, AS2), or corresponding vector (MCF10A-Neo) were cultured in the same medium except that it also contained 500 mg/ml of G418 (Life Technologies; Shekhar et al., 2002) .
Western blot analysis
Cell lysates were prepared as previously described in 10 mM Tris-HCl, pH 7.5/150 mM NaCl/1% Triton X-100/1 mM phenyl methylsulfonyl fluoride, 1 mg/ml each of leupeptin, pepstatin, antipain and 1 mM sodium orthovanadate. Proteins RAD6 influences drug sensitivity A Lyakhovich and MPV Shekhar (50 mg) from each lysate were separated by SDS-PAGE and transblotted onto Immobilon P membranes. The blots were stained with anti-RAD6 antibody. Loading of protein was monitored by reprobing stripped membranes with mouse antib actin antibody (Oncogene Science). RAD6 and b-actin protein bands were visualized with anti-rabbit or anti-mouse IgG coupled to horseradish peroxidase, respectively, using the ECL kit (Amersham, Arlington Heights, IL, USA). The RAD6 antibody was generated by multiple immunization of New Zealand white rabbits with a synthetic peptide (K plus amino-acid residues 131-152; accession # NM_009458) that is conserved 100% in mouse and human HR6B, and 91% in human HR6A (Shekhar et al., 2002) . Since the human RAD6A and B proteins share B96% identical amino-acid residues, and the synthetic peptide used for generation of RAD6B differs from RAD6A by only two amino acids, the levels of RAD6 proteins expressed by RAD6A and B are not distinguishable. Thus, the 17 kDa RAD6-immunoreactive protein(s) detected in human cells are regarded as RAD6 rather than RAD6A or RAD6B (Shekhar et al., 2002) .
Analysis of RAD6 expression during cell cycle
MCF10A cells were synchronized by serum starvation for 72 h and released from G0 phase by stimulating them with complete medium for 8-10 h. Cells were treated overnight with 5 mM 5-hydroxyurea (a G1/S-blocking drug) in complete medium, washed to remove hydroxyurea and further incubated in drugfree complete medium. Cells were harvested during quiescent phase, following treatment with hydroxyurea and at various times after release from hydroxyurea for the analysis of cell cycle progression and RAD6 protein expression by flow cytometry and Western blot analysis, respectively.
Flow cytometry
MCF10A cells (quiescent, 5-hydroxyurea-treated or postrelease from 5-hydroxyurea) were trypsinized into single-cell suspension, fixed in ice-cold 70% ethanol and stored at 41C until required. Before analysis, cells were resuspended in 100 mg/ml RNase A (Promega Corp., Madison, WI, USA), 40 mg/ml propidium iodide and sodium phosphate-buffered saline. Analysis was performed on a Becton Dickinson fluorescence activated cell sorter (FACScan).
RT-PCR
RAD6B mRNA expression was measured by semiquantitative RT-PCR. MCF10A cells were either untreated or treated with 0.1 mg/ml ADR for 1 h, cells rinsed and replaced with drug-free media. At various times of recovery following ADR treatment, total RNA was isolated and treated with RNase-free DNase I. A measure of 2 mg of DNase I-treated total RNA was reverse transcribed with SuperScriptII and 2 ml aliquot was used for PCR amplification of 5 0 UTR of RAD6B cDNA. The PCR reactions contained RAD6B-specific primers þ 18/ þ 38 and þ 420/ þ 399 (accession # M74525) as forward and reverse primers, respectively, and conditions that yielded a detectable PCR product using the minimum number of amplification cycles. Amplification of GAPDH cDNA was included as an internal control for the amount of cDNA tested. The GAPDH-specific primers were þ 186/ þ 206 and þ 320/ þ 302 (accession # XM_006959) as forward and reverse primers, respectively. PCR was conducted for 22 cycles as it yielded products within the linear range of amplification of RAD6B cDNA. The PCR products were separated on agarose gels and ethidium bromide-stained bands were analysed by densitometry (Model 300A densitometer, Molecular Dynamics, Sunnyvale, CA, USA). The authenticity of the amplified sequences was verified by nested PCR using RAD6B-specific primers and sequence analysis.
Measurement of mRNA decay
MCF10A cells were treated with 0.1 mg/ml ADR for 1 h, and then rinsed and allowed to recover for 4 h at which time both control and ADR-treated cells were incubated with the transcriptional inhibitor actinomycin D (5 mg/ml). Total RNA was extracted, DNase I-treated, and RAD6B mRNA levels were monitored at various times by the slot blot method. Filters were hybridized overnight with a random-primed 32 P-labeled RAD6B-specific cDNA probe in buffer containing 6 Â SSC, 50% formamide and 0.5% SDS. Filters were washed with 1 Â SSC and radiolabeled signals were recorded on Storm 860 phosphorimager (Molecular Dynamics). The 5 0 UTR of RAD6B-specific cDNA was amplified from DNAse I-treated MCF10A RNA using RAD6B-specific þ 18/ þ 38 and þ 420/ þ 399 as forward and reverse primers, respectively (accession # M74525). The intensities of RAD6B-hybridizing bands from parallel experiments performed in the presence and absence of actinomycin D were quantitated by densitometry (Molecular Dynamics).
Measurement of protein stability
Control and ADR-treated MCF10A cells were prepared as described above, and treated with actinomycin D (5 mg/ml) or cycloheximide (10 mg/ml) to inhibit new gene expression or protein synthesis, respectively. The levels of RAD6 protein were detected by Western blot analysis from cell lysates prepared at 0, 2, 12 or 24 h following actinomycin D or cycloheximide treatment. Blots were stripped and reprobed with p53 CM-1 polyclonal antibody (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK) to validate the efficacy of actinomycin D and cycloheximide treatments. Amounts of RAD6 (HR6A/HR6B) and p53 protein(s) were quantitated with a scanner densitometer (Molecular Dynamics).
In vivo crosslinking
Control and ADR-treated MCF10A cells prepared as described above were fixed with 1% formaldehyde for 30 min at 371C, and fixing was stopped by addition of 0.125 M glycine (Solomon and Varshavsky, 1985) . Cells were washed, pelleted and lysed with buffer containing 0.5% NP-40. Nuclei were sedimented and nuclei lysed with buffer containing 0.25% Triton X-100 and 1 mM EGTA. The crosslinked chromatin was sheared by sonication, adjusted to 0.5% sarkosyl, and centrifuged at 7000 g. The supernatants were overlaid onto 5 ml of 1.42 g/cm 3 CsCl in the same sarkosyl buffer and subjected to isopycnic ultracentrifugation at 45 000 g for 72 h at 151C. Fractions of 0.5 ml were collected from the bottom of the tube, concentrated using Centricon filters, and CsCl was eliminated by consecutive dilution with 10 mM Tris-HCl, pH 7.5. The presence of DNA in the nuclear fractions was determined by agarose gel electrophoresis and ethidium bromide staining. The presence of RAD6, p53, RAD18, PCNA and phosphohistone H3 (a DNA marker) in fractions was determined by SDS-PAGE and Western blot analysis using antibodies specific for RAD6 (1), p53 (pAb421, Oncogene Science), human RAD18 (Imgenex, San Diego, CA, USA), PCNA (Dako Corp.) and phosphohistone H3 (Upstate Biochemicals). Blots were also probed with anticarboxypeptidase A antibody (Sigma-Aldrich Company, St Louis, MO, USA), a cytoplasmic protein to verify the absence of contaminating cytoplasmic proteins in nuclear extracts.
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